It took a while for columnist Kylene Henderson's husband, Donnie, to be diagnosed with an autoimmune disease that led to ...

The activity levels of four genes linked to the Notch pathway could help in achieving an earlier diagnosis of idiopathic ...

The European Medicines Agency has granted orphan drug status to LTI-03, an inhaled therapy being developed for people with ...

Artificial intelligence has come a long way, writes columnist Sam Kirton, who argues for its role in medicine and in his own care with PF.

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” Danoff is also a professor of ...

New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary fibrosis.

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).